Nautilus Biotechnology, Inc. (NAUT) Key Metrics
NAUT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $262.1M
- Enterprise value
- $65.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.9 10-yr median 1.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.73
NAUT key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNAUT valuation Price multiples at each fiscal year-end price.
NAUT returns How much profit the business earns on the capital it uses.
NAUT per-share figures Results divided by the shares outstanding at year-end.
NAUT financial health Debt, liquidity and how easily interest is covered.
NAUT efficiency & capital use Working capital cycle and where the cash goes.
NAUT valuation history
NAUT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NAUT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NAUT cash returned to shareholders
NAUT price vs earnings per share
NAUT key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $246.2M | $210.7M | $373.5M | $224.3M | $437.5M | $358.8M | — | — |
| Enterprise value | $172.8M | $111.3M | $234.7M | $70.1M | $121.8M | $286.8M | — | — |
| Price / book | 1.6 | 1.0 | 1.4 | 0.7 | 1.2 | — | — | — |
| Earnings yield | −24.0% | −33.6% | −17.0% | −25.8% | −11.5% | −4.4% | — | — |
| Free cash flow yield | −21.1% | −29.1% | −14.5% | −21.5% | −9.5% | −4.2% | — | — |
| Dividend yield | — | — | — | — | — | 0.0% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | 1.8% | 0.0% | — | — |
| Share price at fiscal year-end | $1.95 | $1.68 | $2.99 | $1.80 | $5.18 | $10.85 | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$0.47 | −$0.56 | −$0.51 | −$0.46 | −$0.60 | −$0.47 | — | — |
| Operating cash flow per share | −$0.40 | −$0.47 | −$0.41 | −$0.37 | −$0.46 | −$0.42 | — | — |
| Free cash flow per share | −$0.41 | −$0.49 | −$0.43 | −$0.39 | −$0.49 | −$0.45 | — | — |
| Cash per share | $0.82 | $1.04 | $1.39 | $1.48 | $4.09 | $2.32 | — | — |
| Book value per share | $1.24 | $1.66 | $2.12 | $2.53 | $4.30 | −$0.90 | — | — |
| Tangible book value per share | $1.24 | $1.66 | $2.12 | $2.53 | $4.30 | −$0.90 | — | — |
| Dividends per share | — | — | — | — | — | $0.00 | — | — |
| Capex per share | $0.01 | $0.02 | $0.02 | $0.02 | $0.03 | $0.03 | — | — |
| Debt per share | $0.24 | $0.24 | $0.28 | $0.24 | $0.36 | $0.14 | — | — |
| Shares outstanding | 126.3M | 125.4M | 124.9M | 124.6M | 84.5M | 33.1M | — | — |
| Change in shares outstanding | +0.7% | +0.4% | +0.3% | +47.5% | +155.4% | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −32.3% | −29.9% | −21.9% | −17.1% | −30.1% | — | −83.4% | — |
| Return on invested capital (ROIC) | −54.7% | −54.6% | −41.9% | −48.2% | — | — | — | — |
| Return on assets (ROA) | −27.2% | −25.8% | −19.4% | −15.5% | −20.8% | −30.2% | −11.7% | 429.7% |
| Return on tangible assets | −30.9% | −29.2% | −20.8% | −16.5% | −12.6% | −18.4% | −51.9% | 429.7% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | −0.38 |
| Financial health | ||||||||
| Total debt | $30.0M | $30.5M | $34.6M | $30.3M | $30.0M | $4.8M | $275.0M | $5.0M |
| Cash & short-term investments | $103.4M | $129.9M | $173.4M | $184.5M | $345.7M | $76.7M | $16.7M | $144.49B |
| Net debt | −$73.4M | −$99.4M | −$138.8M | −$154.1M | −$315.7M | −$72.0M | $258.3M | −$144.48B |
| Debt / equity | 0.19 | 0.15 | 0.13 | 0.10 | 0.08 | — | 15.23 | 1.00 |
| Debt / assets | 0.16 | 0.13 | 0.11 | 0.09 | 0.08 | 0.06 | 14.83 | 0.03 |
| Net debt / EBITDA | — | — | — | — | — | — | — | −230.58 |
| Current ratio | 13.33 | 17.40 | 19.39 | 27.57 | 60.09 | 25.73 | 34.62 | 266.45 |
| Quick ratio | 13.33 | 17.40 | 19.39 | 27.57 | 60.09 | 25.73 | 34.62 | 266.45 |
| Interest coverage | — | — | — | -10.9 | -275.9 | — | — | — |
| Working capital | $98.0M | $125.2M | $167.7M | $180.4M | $343.4M | $74.6M | $16.5M | $1.3M |
| Invested capital | $83.6M | $109.3M | $126.6M | $160.8M | $47.9M | −$101.7M | $276.4M | −$144.48B |
| Tangible asset value | $157.0M | $208.7M | $265.4M | $314.9M | $363.6M | −$29.7M | $18.1M | $5.0M |
| Net current asset value | $71.8M | $98.8M | $136.6M | $152.1M | $314.3M | −$37.1M | $16.5M | −$139.5M |
| Graham net-net per share | $0.55 | $0.76 | $1.07 | $1.20 | $3.68 | −$1.15 | — | — |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | — | $52,952 | — | — |
| Share buybacks (net) | $0 | $0 | $0 | $0 | $8.0M | $0 | $874,326 | $1.2M |
| Capex / depreciation | 0.20 | 0.33 | 0.43 | 0.68 | 0.80 | 0.39 | 1.69 | 0.00 |
| Efficiency | ||||||||
| Days payables outstanding | 54.5 | 75.4 | 93.1 | 160.0 | 140.8 | 59.0 | — | — |
| Payables turnover | 6.70 | 4.84 | 3.92 | 2.28 | 2.59 | 6.18 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $965,000 | $1.3M | $1.5M | $1.5M | $1.1M | $379,500 | $289,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NAUT's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NAUT valuation and financial ratios
Nautilus Biotechnology earned a return on equity of −32.3% and a return on invested capital of −54.7% in fiscal 2025. It ended the year with $30.0 million of debt and $103.4 million in cash and short-term investments, a net cash position of $73.4 million.
See the NAUT income statement, the NAUT chart for price history, or the NAUT stock overview for the latest quote and news.
NAUT key metrics FAQ
What is Nautilus Biotechnology's return on equity?
Nautilus Biotechnology's return on equity (ROE) was −32.3% in fiscal 2025: net income of -$59.0 million on average shareholders' equity of $182.9 million.
What is Nautilus Biotechnology's ROIC?
Nautilus Biotechnology's return on invested capital was −54.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Nautilus Biotechnology have?
Nautilus Biotechnology had total debt of $30.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.19 and more cash than debt.
What is Nautilus Biotechnology's free cash flow yield?
Nautilus Biotechnology generated -$52.0 million of free cash flow in fiscal 2025, a free cash flow yield of −21.1% on its market value at year-end ($246.2 million).
What is Nautilus Biotechnology's current ratio?
Nautilus Biotechnology's current ratio was 13.33 at the end of fiscal 2025: current assets were 13.33 times current liabilities.